EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Heart Failure with Reduced EF and Mortality After TEVAR for Type B Dissection

Suko Adiarto, Hamzah Pratama Megantara, Ayers Gilberth Ivano Kalaij, Taofan Taofan, Suci Indriani, Ruth Grace Aurora, Iwan Dakota

International Journal of Angiology · 2026-09-08

DOI: 10.1055/a-2947-0784 ↗
AbstractBibliografische Angaben

Abstract

Abstract Thoracic endovascular aortic repair (TEVAR) is established for type B aortic dissection (TBAD), but the longer-term relevance of baseline left ventricular systolic dysfunction remains uncertain. To explore the association between preprocedural heart failure with reduced ejection fraction (HFrEF) and all-cause mortality after TEVAR for TBAD. We retrospectively studied consecutive patients with TBAD who underwent TEVAR at a tertiary cardiovascular center from 2014 through 2022. HFrEF was defined as left ventricular ejection fraction ≤40%. Survival was estimated by Kaplan-Meier analysis, and exploratory univariable Cox regression was used because only 16 deaths occurred. Of 81 eligible patients 14 were lost to follow-up and excluded from the primary time-to-event analysis; a post hoc extreme-case analysis bounded the crude mortality proportion among all eligible patients. Sixty-seven patients were analyzed over a mean follow-up of 49.2 months (95% confidence interval [CI]: 44.2–54.3); 16 died (23.9%). Seven patients had HFrEF, including five deaths. HFrEF was associated with higher mortality (hazard ratio, 5.65; 95% CI: 1.95–16.36; p = 0.001). Estimated mean survival was 24.2 months (95% CI: 5.7–43.1) with HFrEF and 52.2 months (95% CI: 47.5–56.9) without HFrEF. Depending on the unknown outcomes of the 14 patients lost to follow-up, crude mortality among all 81 eligible patients would range from 19.8 to 37.0%. Baseline HFrEF showed a strong unadjusted association with long-term mortality after TEVAR for TBAD. The small exposed subgroup, limited event count, unmeasured confounding, and attrition preclude claims of an independent or TEVAR-specific prognostic effect; the finding is hypothesis-generating.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →